Divalproex Sodium Tablet, Delayed Release
Product Images NDC 71335-2277

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 71335-2277). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713352277)

Label for Divalproex Sodium Delayed Release Tablets, USP 250 mg, in a 30 tablet package. The product is repackaged by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by Sun Pharmaceutical Industries Inc. The label includes storage instructions, a barcode, and a warning to keep out of reach of children.*

FDA Label Image

Spl-divalproex-figure-1 (Spl Divalproex Figure 1)

A bar chart titled 'Figure 1' showing percentage values comparing PBO (placebo) and DVPX (divalproex sodium) across two studies. Study 1 (YMRS) shows 26% for PBO and 60% for DVPX, while Study 2 (MRS) shows 29% for PBO and 58% for DVPX. Percentages are on the vertical axis, with treatment groups and study labels on the horizontal axis.*

FDA Label Image

Spl-divalproex-figure-2 (Spl Divalproex Figure 2)

A comparative cumulative percentage curve graph showing the percentage reduction in clinical parameter score (CPS Rate) for patients treated with Divalproex Sodium (DVPX) versus placebo. The vertical axis represents percentage reduction in CPS rate, ranging from -100% to 100%, indicating worsening to improvement. The horizontal axis represents the percentage of patients from 0 to 100%. Solid and dashed lines represent DVPX and placebo groups, respectively.*

FDA Label Image

Spl-divalproex-figure-3 (Spl Divalproex Figure 3)

A figure graph titled 'Figure 3' showing the percentage reduction in CPS rate on the vertical axis versus the percentage of patients on the horizontal axis. The graph compares two lines labeled 'High Dose' and 'Low Dose', illustrating patient response categorized as improvement, no change, or worsening in CPS rate.*

FDA Label Image

Spl-divalproex-figure-4 (Spl Divalproex Figure 4)

A bar graph titled 'Figure 4 Mean 4-week Migraine Rates' showing migraine rates for Placebo and Divalproex Sodium (DVPX) groups in two studies. Study 1 and Study 2 each compare migraine rates between placebo and DVPX groups, with bars indicating lower migraine rates for DVPX in both studies.*

FDA Label Image

Spl-divalproex-structure (Spl Divalproex Structure)

Chemical structure of Divalproex Sodium, depicting its polymeric composition with sodium carboxylate groups and branched alkyl chains.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.